S. Špánik

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study

Michal Mego, Jozef Chovanec, Iveta Vochyanova-Andrezalova et al. · Complementary Therapies in Medicine · 2015 · 222 citations

Probiotic, Dysbiosis, Medicine +7

Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors

Zuzana Čierna, Michal Mego, Věra Miškovská et al. · Annals of Oncology · 2015 · 161 citations · Full text

Programmed-death-1 Receptor, Germ Cell, Malignant Disease +10

Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol

V. Krčméry, F Mateička, A. Kunová et al. · Supportive Care in Cancer · 1999 · 105 citations

Radiation Oncology, Hematogenous Trichosporonosis, Cancer Patients +1

Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome

V. Krčméry, E. Oravcová, S. Špánik et al. · Journal of Antimicrobial Chemotherapy · 1998 · 101 citations · Full text

Pathology, Clinical Mycology, Antimicrobial Chemotherapy +19